Evaluation of Preimplantation Portal Vein and Hepatic Artery Flushing With Tacrolimus (PATAC)
Early Allograft Dysfunction, Ischemic Reperfusion Injury, Liver Transplantation
About this trial
This is an interventional prevention trial for Early Allograft Dysfunction focused on measuring Liver transplantation, Early allograft dysfunction, Ischemic reperfusion injury, Portal and arterial ex vivo HTK flush
Eligibility Criteria
Inclusion Criteria:
- Donor:
age 15-65 years macrovesicular steatosis < 40% (macroscopy or biopsy) sodium <165 mmol/l ICU stay and ventilation < 11 days cold ischemia time < 13 hours AST < 200 U/l ALT < 200 U/l bilirubin < 50 μmol/l application of norepinephrine is allowed
- Recipient age: 18-69
Exclusion Criteria:
Recipient:
- live donor liver transplant
- reduced and split grafts
- multi organ failure
Sites / Locations
- RSPC for organ and tissue transplantation, Minsk 9th clinic
Arms of the Study
Arm 1
Arm 2
Experimental
No Intervention
Tacrolimus + HTK
HTK
During back-table operation 1000 ml of HTK solution cooled to 2-4˚C containing 20 ng/ml Tacrolimus would be given through intraportal (under gravity pressure of 40 cm H2O) and intraarterial infusion (under pressure of 40-50 mm Hg) followed by intraportal infusion of 200 ml 5% solution of Albumin containing 20 ng/ml Tacrolimus under gravity pressure of 40 cm H2O.
During back-table operation 1000 ml of HTK solution cooled to 2-4˚C would be given through intraportal (under gravity pressure of 40 cm H2O) and intraarterial infusion (under pressure of 40-50 mm Hg) followed by intraportal infusion of 200 ml 5% solution of Albumin under gravity pressure of 40 cm H2O.